As of 2025-09-16, the Relative Valuation of Arrowhead Pharmaceuticals Inc (ARWR) is (17.01) USD. This relative valuation is based on P/E multiples. With the latest stock price at 28.67 USD, the upside of Arrowhead Pharmaceuticals Inc based on Relative Valuation is -159.3%.
The range of the Relative Valuation is (15.41) - (19.79) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.4x - 18.4x | 17.4x |
| Forward P/E multiples | 13.7x - 18.5x | 14.3x |
| Fair Price | (15.41) - (19.79) | (17.01) |
| Upside | -153.8% - -169.0% | -159.3% |
| Date | P/E |
| 2025-09-10 | -26.91 |
| 2025-09-09 | -25.83 |
| 2025-09-08 | -25.31 |
| 2025-09-05 | -27.09 |
| 2025-09-04 | -26.08 |
| 2025-09-03 | -25.90 |
| 2025-09-02 | -23.92 |
| 2025-08-29 | -20.52 |
| 2025-08-28 | -20.81 |
| 2025-08-27 | -20.30 |
| 2025-08-26 | -19.73 |
| 2025-08-25 | -19.29 |
| 2025-08-22 | -19.87 |
| 2025-08-21 | -19.33 |
| 2025-08-20 | -18.82 |
| 2025-08-19 | -18.50 |
| 2025-08-18 | -18.55 |
| 2025-08-15 | -19.11 |
| 2025-08-14 | -17.49 |
| 2025-08-13 | -18.62 |
| 2025-08-12 | -16.58 |
| 2025-08-11 | -16.03 |
| 2025-08-08 | -15.30 |
| 2025-08-07 | -14.96 |
| 2025-08-06 | -15.19 |
| 2025-08-05 | -15.34 |
| 2025-08-04 | -15.34 |
| 2025-08-01 | -14.84 |
| 2025-07-31 | -14.72 |
| 2025-07-30 | -14.63 |
| 2025-07-29 | -14.83 |
| 2025-07-28 | -15.09 |
| 2025-07-25 | -14.66 |
| 2025-07-24 | -15.15 |
| 2025-07-23 | -14.83 |
| 2025-07-22 | -13.94 |
| 2025-07-21 | -13.70 |
| 2025-07-18 | -15.61 |
| 2025-07-17 | -17.56 |
| 2025-07-16 | -17.05 |
| 2025-07-15 | -16.42 |
| 2025-07-14 | -17.34 |
| 2025-07-11 | -17.06 |
| 2025-07-10 | -17.57 |
| 2025-07-09 | -17.59 |
| 2025-07-08 | -16.34 |
| 2025-07-07 | -15.69 |
| 2025-07-03 | -15.64 |
| 2025-07-02 | -15.74 |
| 2025-07-01 | -14.99 |